In recent years, there has been a significant increase in the diagnosis of asymptomatic Late-Onset Pompe Disease (LOPD) patients, who are detected via family screening or Newborn Screening (NBS). The dilemma is when to start Enzyme Replacement Therapy (ERT) in patients without any clinical sign of the disease, considering its important benefits in terms of loss of muscle but also its very high cost, risk of side effects, and long-term immunogenicity. Muscle Magnetic Resonance Imaging (MRI) is accessible, radiation-free, and reproducible; therefore, it is an important instrument for the diagnosis and follow-up of patients with LOPD, especially in asymptomatic cases. European guidelines suggest monitoring in asymptomatic LOPD cases with minimal MRI findings, although other guidelines consider starting ERT in apparently asymptomatic cases with initial muscle involvement (e.g., paraspinal muscles). We describe three siblings affected by LOPD who present compound heterozygosis and wide phenotypic variability. The three cases differ in age at presentation, symptoms, urinary tetrasaccharide levels, and MRI findings, confirming the significant phenotypic variability of LOPD and the difficulty in deciding when to start therapy.

Faraguna, M., Crescitelli, V., Fornari, A., Barzaghi, S., Savasta, S., Foiadelli, T., et al. (2023). Treatment Dilemma in Children with Late-Onset Pompe Disease. GENES, 14(2) [10.3390/genes14020362].

Treatment Dilemma in Children with Late-Onset Pompe Disease

Faraguna, Martha Caterina;Crescitelli, Viola;Fornari, Anna;Barzaghi, Silvia;
2023

Abstract

In recent years, there has been a significant increase in the diagnosis of asymptomatic Late-Onset Pompe Disease (LOPD) patients, who are detected via family screening or Newborn Screening (NBS). The dilemma is when to start Enzyme Replacement Therapy (ERT) in patients without any clinical sign of the disease, considering its important benefits in terms of loss of muscle but also its very high cost, risk of side effects, and long-term immunogenicity. Muscle Magnetic Resonance Imaging (MRI) is accessible, radiation-free, and reproducible; therefore, it is an important instrument for the diagnosis and follow-up of patients with LOPD, especially in asymptomatic cases. European guidelines suggest monitoring in asymptomatic LOPD cases with minimal MRI findings, although other guidelines consider starting ERT in apparently asymptomatic cases with initial muscle involvement (e.g., paraspinal muscles). We describe three siblings affected by LOPD who present compound heterozygosis and wide phenotypic variability. The three cases differ in age at presentation, symptoms, urinary tetrasaccharide levels, and MRI findings, confirming the significant phenotypic variability of LOPD and the difficulty in deciding when to start therapy.
Articolo in rivista - Articolo scientifico
Enzyme Replacement Therapy; glycogen storage disease type 2; late onset; muscle MRI; Pompe disease;
English
30-gen-2023
2023
14
2
362
open
Faraguna, M., Crescitelli, V., Fornari, A., Barzaghi, S., Savasta, S., Foiadelli, T., et al. (2023). Treatment Dilemma in Children with Late-Onset Pompe Disease. GENES, 14(2) [10.3390/genes14020362].
File in questo prodotto:
File Dimensione Formato  
Faraguna-2023-Genes-VoR.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Creative Commons
Dimensione 425.11 kB
Formato Adobe PDF
425.11 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/481479
Citazioni
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
Social impact